Department of Orthopedic Surgery and Biomedical Research Institute, 220312Pusan National University Hospital, Seo-gu, Busan, Republic of Korea.
Department of Orthopedic Surgery, 194197Pusan National University Yangsan Hospital, Mulgeum-eup, Yangsan, Republic of Korea.
J Orthop Surg (Hong Kong). 2020 Sep-Dec;28(3):2309499020952893. doi: 10.1177/2309499020952893.
This study aimed to evaluate the feasibility and effect of triamcinolone acetonide (TA) injection for lateral malleolar (LM) bursitis.
We retrospectively reviewed data of 49 consecutive patients (49 ankles) who received TA injection between March 2016 and March 2019. All cases received 1 ml (40 mg) of TA injection after aspiration of fluid in the LM bursal sac. Subsequently, the ankle was compressed with an elastic cohesive bandage for 2 weeks. Treatment responses were assessed according to the degree of fluctuation, shrinkage of the bursal sac, and soft tissue swelling. We used the Medical Outcomes Study Short Form Health Survey (SF-36) and complications at 2 and 4 weeks and at 3 and 6 months after TA injection.
Forty-four patients (89.8%) experienced complete resolution, four (8.2%) had partial resolution, and one (2.0%) had no resolution after the first or second TA injection. The physical component scores of SF-36 improved from 72.8 ± 6.0 to 82.3 ± 6.5 at the last follow-up ( < 0.001). Associated complications included skin atrophy in three patients (6.1%) and transient hyperglycemia in four (8.2%).
TA injection is an effective and safe procedure for LM bursitis. It should be considered as a primary treatment method.
本研究旨在评估曲安奈德（TA）注射治疗外踝滑囊炎的可行性和效果。
我们回顾性分析了 2016 年 3 月至 2019 年 3 月期间连续 49 例（49 例踝关节）接受 TA 注射的患者资料。所有患者均在抽吸外踝滑囊积液后接受 1ml（40mg）TA 注射。随后，踝关节用弹性粘性绷带加压 2 周。根据波动程度、滑囊收缩和软组织肿胀来评估治疗反应。我们使用医疗结局研究短表健康调查（SF-36）和 TA 注射后 2 周、4 周、3 个月和 6 个月时的并发症来评估。
44 例（89.8%）患者在第一次或第二次 TA 注射后完全缓解，4 例（8.2%）部分缓解，1 例（2.0%）无缓解。SF-36 的生理成分评分从治疗前的 72.8±6.0 分提高到最后随访时的 82.3±6.5 分（<0.001）。相关并发症包括 3 例（6.1%）皮肤萎缩和 4 例（8.2%）一过性高血糖。
TA 注射是治疗外踝滑囊炎的有效且安全的方法，应作为首选治疗方法。
